Aim: To carry out a systematic review of the available evidence from health decision makers, patients, and therapists regarding the ability of Baclofen use in decreasing alcohol withdrawal symptoms to patients in inpatient settings. acute care setting. Methodology: Systematic searches were carried out on the following databases: Academic Search Premier, CINAHL, Cochrane and PsycINFO via EBSCO Host, Embase, MEDLINE via PubMed, and Web of Science. The last search date was May 28, 2019. The search was limited to the last 10 years, i.e., from January 1st, 2010. Findings: Four studies were included in the final review. The total population was 258 patients. The studies did not report any statistically significant difference between Baclofen to p...
PURPOSE: Benzodiazepines are the drugs of choice in the treatment of alcohol withdrawal syndrome (AW...
International audienceBackground: Baclofen is a GABA-B receptor agonist currently used in the treatm...
Aims: The γ-aminobutyric acid (GABAB) receptor agonist, baclofen, has recently been shown to reduce ...
Aim: To carry out a systematic review of the available evidence from health decision makers, patient...
The Alcohol Withdrawal Syndrome (AWS), which may occur with or without delirium, is a frequent conse...
Recent clinical trials and case-reports indicate that baclofen, a GABAB agonist, may have efficacy f...
Background: Alcohol withdrawal syndrome (AWS) increases the complexity of inpatient medical care. Ba...
Summary Recent preclinical and clinical studies have suggested that baclofen, the prototypic γ-amin...
Background Alcohol use disorder (AUD) is one of the most widespread psychiatric disorder leading to...
Background and Aims There are a limited number of pharmacotherapies licensed for alcohol use disorde...
Aim: To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the trea...
Both preclinical and clinical research studies have shown the GABA(B) receptor agonist baclofen repr...
ObjectiveTo evaluate the efficacy and tolerability of baclofen vs. placebo for long-term treatment o...
Aims: The purpose of this study was to examine the long-term effects of baclofen in a large cohort o...
Review question: This review attempted to evaluate the efficacy and safety of baclofen as a therapy ...
PURPOSE: Benzodiazepines are the drugs of choice in the treatment of alcohol withdrawal syndrome (AW...
International audienceBackground: Baclofen is a GABA-B receptor agonist currently used in the treatm...
Aims: The γ-aminobutyric acid (GABAB) receptor agonist, baclofen, has recently been shown to reduce ...
Aim: To carry out a systematic review of the available evidence from health decision makers, patient...
The Alcohol Withdrawal Syndrome (AWS), which may occur with or without delirium, is a frequent conse...
Recent clinical trials and case-reports indicate that baclofen, a GABAB agonist, may have efficacy f...
Background: Alcohol withdrawal syndrome (AWS) increases the complexity of inpatient medical care. Ba...
Summary Recent preclinical and clinical studies have suggested that baclofen, the prototypic γ-amin...
Background Alcohol use disorder (AUD) is one of the most widespread psychiatric disorder leading to...
Background and Aims There are a limited number of pharmacotherapies licensed for alcohol use disorde...
Aim: To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the trea...
Both preclinical and clinical research studies have shown the GABA(B) receptor agonist baclofen repr...
ObjectiveTo evaluate the efficacy and tolerability of baclofen vs. placebo for long-term treatment o...
Aims: The purpose of this study was to examine the long-term effects of baclofen in a large cohort o...
Review question: This review attempted to evaluate the efficacy and safety of baclofen as a therapy ...
PURPOSE: Benzodiazepines are the drugs of choice in the treatment of alcohol withdrawal syndrome (AW...
International audienceBackground: Baclofen is a GABA-B receptor agonist currently used in the treatm...
Aims: The γ-aminobutyric acid (GABAB) receptor agonist, baclofen, has recently been shown to reduce ...